Heparan sulfate functions are altered in the osteoarthritic cartilage.
Cartilage matrix
Chondrocytes
Heparan sulfate
Osteoarthritis
Sulfation
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
07 12 2020
07 12 2020
Historique:
received:
06
06
2020
accepted:
12
10
2020
entrez:
8
12
2020
pubmed:
9
12
2020
medline:
22
6
2021
Statut:
epublish
Résumé
Heparan sulfate (HS) proteoglycans (PG) may be found at the chondrocyte surface and in the pericellular cartilage matrix, and are involved in cell-cell and cell-matrix interactions. An important function of HS chains is to regulate cell fate through specific interactions with heparin-binding proteins (HBP) modulated by their complex sulfation pattern. Osteoarthritis (OA) is a joint disorder characterized by the degradation of articular cartilaginous extracellular matrix. The aim of this study was to investigate HS structure and functions in osteoarthritic cartilages compared to normal cartilages (controls). Glycosaminoglycans (GAG) were extracted from human macroscopically normal cartilages (controls, n = 7) and (OA cartilages n = 11). HS were isolated and quantified using the DMMB quantification method. Their structure and functions were then compared using respectively a HPLC analysis and HBP binding tests and their phenotypic effects on murine chondrocytes were studied by RQ-PCR. Statistical analyzes were performed using a one-way ANOVA followed by a Dunnett's test or a t test for pairwise comparisons. In OA, HS were characterized by increased sulfation levels compared to controls. Moreover, the capacity of these HS to bind HBP involved in the OA pathophysiological process such as FGF2 and VEGF was reduced. Chondroitin sulfates and keratan sulfates regulated these binding properties. Finally, HS from OA cartilages induced the mRNA levels of catabolic markers such as MMP3, MMP13, and TS4 and inhibited the mRNA levels of anabolic markers such as COL2, ACAN, SOX9, and VEGF in murine articular chondrocytes. The sulfation of HS chains was increased in OA cartilages with changes in HBP binding properties and biological effects on chondrocyte phenotypes. Thus, modified HS present in altered cartilages could be a novel therapeutic target in OA.
Sections du résumé
BACKGROUND
Heparan sulfate (HS) proteoglycans (PG) may be found at the chondrocyte surface and in the pericellular cartilage matrix, and are involved in cell-cell and cell-matrix interactions. An important function of HS chains is to regulate cell fate through specific interactions with heparin-binding proteins (HBP) modulated by their complex sulfation pattern. Osteoarthritis (OA) is a joint disorder characterized by the degradation of articular cartilaginous extracellular matrix. The aim of this study was to investigate HS structure and functions in osteoarthritic cartilages compared to normal cartilages (controls).
METHODS
Glycosaminoglycans (GAG) were extracted from human macroscopically normal cartilages (controls, n = 7) and (OA cartilages n = 11). HS were isolated and quantified using the DMMB quantification method. Their structure and functions were then compared using respectively a HPLC analysis and HBP binding tests and their phenotypic effects on murine chondrocytes were studied by RQ-PCR. Statistical analyzes were performed using a one-way ANOVA followed by a Dunnett's test or a t test for pairwise comparisons.
RESULTS
In OA, HS were characterized by increased sulfation levels compared to controls. Moreover, the capacity of these HS to bind HBP involved in the OA pathophysiological process such as FGF2 and VEGF was reduced. Chondroitin sulfates and keratan sulfates regulated these binding properties. Finally, HS from OA cartilages induced the mRNA levels of catabolic markers such as MMP3, MMP13, and TS4 and inhibited the mRNA levels of anabolic markers such as COL2, ACAN, SOX9, and VEGF in murine articular chondrocytes.
CONCLUSION
The sulfation of HS chains was increased in OA cartilages with changes in HBP binding properties and biological effects on chondrocyte phenotypes. Thus, modified HS present in altered cartilages could be a novel therapeutic target in OA.
Identifiants
pubmed: 33287871
doi: 10.1186/s13075-020-02352-3
pii: 10.1186/s13075-020-02352-3
pmc: PMC7722421
doi:
Substances chimiques
Glycosaminoglycans
0
Heparitin Sulfate
9050-30-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
283Références
Biochem Biophys Res Commun. 1995 Jun 6;211(1):262-7
pubmed: 7779094
Annu Rev Biochem. 2005;74:385-410
pubmed: 15952892
Ann Biomed Eng. 2016 May;44(5):1325-54
pubmed: 26987846
Joint Bone Spine. 2012 Dec;79(6):597-603
pubmed: 22726638
Dev Dyn. 1997 Oct;210(2):130-45
pubmed: 9337134
J Cell Biochem. 2013 Apr;114(4):735-42
pubmed: 23060229
J Biol Chem. 1992 May 25;267(15):10337-41
pubmed: 1587820
Glycobiology. 2003 Sep;13(9):647-53
pubmed: 12773478
Nat Protoc. 2008;3(8):1253-60
pubmed: 18714293
Cell Mol Life Sci. 2005 Oct;62(19-20):2241-56
pubmed: 16143826
Proc Natl Acad Sci U S A. 2010 Jun 1;107(22):10202-7
pubmed: 20479257
Proteomics. 2008 Apr;8(7):1384-97
pubmed: 18318007
Brain. 2015 May;138(Pt 5):1339-54
pubmed: 25842390
J Biol Chem. 2012 Oct 19;287(43):36132-46
pubmed: 22927437
Osteoarthritis Cartilage. 2008 Mar;16(3):279-86
pubmed: 17945514
Growth Horm IGF Res. 2002 Aug;12(4):193-7
pubmed: 12175651
J Biol Chem. 2004 Sep 3;279(36):37368-76
pubmed: 15226297
Arthritis Rheumatol. 2014 Nov;66(11):3028-39
pubmed: 25080367
Am J Pathol. 1997 Apr;150(4):1443-55
pubmed: 9094999
J Biol Chem. 2006 Jan 20;281(3):1731-40
pubmed: 16258170
J Biol Chem. 1998 Sep 4;273(36):22936-42
pubmed: 9722514
Osteoarthritis Cartilage. 2000 Jul;8(4):294-302
pubmed: 10903884
Eur J Biochem. 1997 Nov 15;250(1):39-46
pubmed: 9431988
J Biol Chem. 2008 Oct 10;283(41):27724-35
pubmed: 18687675
Am J Pathol. 2019 Mar;189(3):632-647
pubmed: 30553836
Curr Drug Discov Technol. 2008 Dec;5(4):289-301
pubmed: 19075609
Biochem J. 2001 Sep 1;358(Pt 2):523-8
pubmed: 11513754
Neurobiol Aging. 2012 May;33(5):1005.e11-22
pubmed: 22035591
J Clin Invest. 1997 Jul 1;100(1):93-106
pubmed: 9202061
J Biol Chem. 2004 Dec 3;279(49):50799-809
pubmed: 15385557
Arthritis Rheum. 1999 Mar;42(3):534-44
pubmed: 10088777
J Biol Chem. 2012 Mar 30;287(14):11363-73
pubmed: 22298772
Glycobiology. 1999 Jul;9(7):705-11
pubmed: 10362840
Annu Rev Cell Biol. 1992;8:365-93
pubmed: 1335744
J Biol Chem. 2010 Sep 3;285(36):27673-85
pubmed: 20584902
Arthritis Rheumatol. 2016 Apr;68(4):868-79
pubmed: 26636652
Histol Histopathol. 2017 Jul;32(7):725-733
pubmed: 27808352
Osteoarthritis Cartilage. 2020 Jul;28(7):977-987
pubmed: 32315715
Arthritis Res Ther. 2008;10(3):R61
pubmed: 18507859
Cytokine. 1997 Dec;9(12):1013-22
pubmed: 9417813
Osteoarthritis Cartilage. 2007 Jul;15(7):752-63
pubmed: 17368052
J Histochem Cytochem. 2012 Dec;60(12):936-42
pubmed: 22899864
J Cell Biochem. 2012 Jul;113(7):2532-42
pubmed: 22415882
J Biol Chem. 2010 May 7;285(19):14247-58
pubmed: 20154082
Chem Biol Drug Des. 2008 Dec;72(6):455-82
pubmed: 19090915
J Clin Invest. 2001 Jul;108(2):169-73
pubmed: 11457867
Cancer Res. 2015 Nov 15;75(22):4753-65
pubmed: 26404004
J Biol Chem. 1993 Nov 15;268(32):23906-14
pubmed: 7693696
Ann Rheum Dis. 1997 Aug;56(8):493-6
pubmed: 9306873
J Biol Chem. 1987 Jun 25;262(18):8926-33
pubmed: 2954956